Pfizer (NYSE:PFE) is currently dealing with shareholder proposals concerning governance issues such as religious ...

Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.

Pfizer offers a 6.7% dividend yield, trading at a low valuation with resilient drug portfolio growth. Realty Income Corp. has ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Calls from far-right figures to 'cleanse' Europe of Muslims and commit a 'Srebrenica 2.0' are now symbolically reinforced by ...

Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Shareholder Yield Investor model based on the published strategy ...

Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

All pharmaceutical manufacturers, including Novo Nordisk (NYSE:NVO) and Teva Pharmaceuticals, have agreed to participate in ...

Representative Julie Johnson (D-Texas) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 12th, the Representative disclosed that they had sold between $1,001 and $15,000 ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...